Related Experiment Videos
The effect of auranofin on polymorphonuclear granulocytes
Scandinavian Journal of Rheumatology. Supplement
|January 1, 1983
Summary
Auranofin impacts neutrophil polymorphonuclear granulocytes (PMN) function, affecting adherence, migration, and bactericidal capacity. It shows biphasic effects on enzyme release and alters receptor binding and membrane potential in PMNs.
Area of Science:
- Immunology
- Pharmacology
Background:
- Neutrophil polymorphonuclear granulocytes (PMNs) are crucial immune cells.
- Auranofin is an anti-rheumatic drug with known immunomodulatory effects.
Purpose of the Study:
- To investigate the in vitro and in vivo effects of auranofin on human neutrophil functions.
- To explore auranofin's impact on PMN adherence, migration, phagocytosis, and enzyme release.
Main Methods:
- In vitro studies using human PMNs exposed to varying concentrations of auranofin.
- In vivo studies in rats and analysis of PMNs from rheumatoid arthritis patients treated with auranofin.
Main Results:
- Auranofin increased PMN adherence and aggregation but inhibited migration, phagocytosis, and bactericidal capacity.
- A biphasic dose-dependent effect was observed on enzyme release, chemoluminescence, and superoxide anion release.
- Auranofin increased 3H-fMLP binding affinity and affected PMN surface charge and membrane potential at higher concentrations.
Conclusions:
- Auranofin modulates various neutrophil functions, with complex dose-dependent effects.
- In rheumatoid arthritis patients, auranofin reduced enzyme release in clinical responders, suggesting a link between drug efficacy and specific immune cell responses.